{"title":"儿童霍奇金淋巴瘤:过去,现在和未来","authors":"A. Weiss, M. Neier, R. Drachtman","doi":"10.2217/PHE.09.60","DOIUrl":null,"url":null,"abstract":"The history of treatment of Hodgkin lymphoma in children and young adults has been one of increasing success, with the focus shifting in recent years from cure, regardless of the cost, to an increasing concern regarding late effects and other consequences of treatment. Ongoing protocols continue to explore the use of risk-based therapy, further delineating the ability to individualize therapy in an effort to decrease morbidity and mortality, while preserving excellent cure rates.","PeriodicalId":88627,"journal":{"name":"Pediatric health","volume":"3 1","pages":"593-606"},"PeriodicalIF":0.0000,"publicationDate":"2009-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/PHE.09.60","citationCount":"1","resultStr":"{\"title\":\"Pediatric Hodgkin lymphoma: Past, present and future\",\"authors\":\"A. Weiss, M. Neier, R. Drachtman\",\"doi\":\"10.2217/PHE.09.60\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The history of treatment of Hodgkin lymphoma in children and young adults has been one of increasing success, with the focus shifting in recent years from cure, regardless of the cost, to an increasing concern regarding late effects and other consequences of treatment. Ongoing protocols continue to explore the use of risk-based therapy, further delineating the ability to individualize therapy in an effort to decrease morbidity and mortality, while preserving excellent cure rates.\",\"PeriodicalId\":88627,\"journal\":{\"name\":\"Pediatric health\",\"volume\":\"3 1\",\"pages\":\"593-606\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/PHE.09.60\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/PHE.09.60\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/PHE.09.60","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pediatric Hodgkin lymphoma: Past, present and future
The history of treatment of Hodgkin lymphoma in children and young adults has been one of increasing success, with the focus shifting in recent years from cure, regardless of the cost, to an increasing concern regarding late effects and other consequences of treatment. Ongoing protocols continue to explore the use of risk-based therapy, further delineating the ability to individualize therapy in an effort to decrease morbidity and mortality, while preserving excellent cure rates.